S
Scohia Pharma
Expanding its strategic partnership with huadong medicine globally for the development of sco-094
About Scohia Pharma
Scohia Pharma is a pioneering pharmaceutical company specializing in the development of innovative medicines targeting lifestyle diseases such as diabetes, obesity, and cardiovascular conditions. The company operates in the highly competitive pharmaceutical market, focusing on creating new chemical entities and advancing them through rigorous medicinal evaluation and clinical development processes. Scohia Pharma serves a diverse client base, including healthcare providers, hospitals, and patients who require advanced therapeutic solutions for chronic conditions.
The business model of Scohia Pharma revolves around extensive research and development (R&D) activities, leveraging a team of experienced scientists and researchers with a strong track record in drug development. The company generates revenue through the commercialization of its proprietary drugs, licensing agreements, and strategic partnerships with other pharmaceutical firms. By maintaining a rich development pipeline and focusing on unmet medical needs, Scohia Pharma aims to deliver high-value treatments that improve patient outcomes and quality of life.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Fujisawa, Japan
- Open positions
- None listed
- Dealroom signal
- 23.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $31M | $125M | SBI Investment · FRONTEO · Bio-sight Capital · Tohoku University Venture Partners | ↗ |
| SERIES BOther financing | Sep 2024 | $3.7M | $15M | SBI Investment · Tohoku University Venture Partners · Gemseki · SRD Holdings | ↗ |
Growth signals
Latest recorded traffic for Scohia Pharma is 1.7K monthly website visits, down 55.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
INCJ
Medipal
Series A5 investors entered at this stage
DBJ Capital
SBI Investment
Tohoku University Venture Partners
Gemseki- SHSRD Holdings
Series B and later7 investors entered at this stage
Takeda
Beyond Next Ventures
FRONTEO
Bio-sight Capital
Daiwa Corporate Investment
Kanagawa Science Park
Kyoto Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scohia Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scohia Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.